Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02848768
  4. Details
NCT02848768 Clinical Trial

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial

— RTKI  

Official title:
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02848768
Other study ID # 35RC14_9896
Secondary ID
Status Completed
Phase N/A
First received July 26, 2016
Last updated July 27, 2016
Start date December 2014

Study information
Verified date July 2016
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Observational

Clinical Trial Summary

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Recruitment information / eligibility
Status Completed
Enrollment 45
Est. completion date
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- patients with metastatic ccRCC

- Underwent nephrectomy at the University Hospital of Rennes

- treated by sunitinib first line treatment

Exclusion Criteria:

- translocation renal cell carcinoma

- other targeted therapies before the sunitinib

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Intervention

Drug:
• Sunitinib

Locations
Country Name City State
France CHU de Rennes Rennes

Sponsors (1)
Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Primary refractory patients (Progression Free Survival (PFS) at 3 months No
See also
  Status Clinical Trial Phase
Completed NCT01510119 - Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT01896271 - High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Phase 2
Recruiting NCT06059014 - Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer Phase 1/Phase 2
Active, not recruiting NCT05122546 - CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Phase 1
Active, not recruiting NCT04904302 - Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Phase 2
Recruiting NCT04510597 - Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial Phase 3
Terminated NCT02781506 - Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT06399419 - CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Phase 1
Not yet recruiting NCT06361810 - PSMA Therapy and Immunotherapy in Kidney Cancer Phase 1/Phase 2
Recruiting NCT06428708 - [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma Early Phase 1
Recruiting NCT04370509 - Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery Phase 2
Recruiting NCT05012371 - Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer Phase 2
Terminated NCT03334409 - Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery Phase 2
Recruiting NCT05361720 - Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Phase 2
Terminated NCT03260504 - Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Phase 1
Completed NCT02002312 - Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Phase 2
Terminated NCT01391130 - A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT04388852 - DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Phase 1
Recruiting NCT05879471 - 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT06349642 - Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform